Hikma Specialty USA Inc.

Hikma Specialty USA Inc., a foreign-owned pharmaceutical manufacturer based in Columbus, Ohio, supplies generic injectable and non-injectable pharmaceutical products to federal healthcare systems and state substance-abuse agencies as a subcontractor (79% of recent awards) and holds a single Federal Supply Schedule contract as a prime. The vendor operates without SBA set-aside designations across its federal footprint and is registered in SAM.gov since May 5, 2016.

Hikma's primary federal customer is the Department of Veterans Affairs Veterans Integrated Service Network 12, which accounts for the full $10 million in combined potential value across recent awards. The vendor holds a multiple-award indefinite delivery Federal Supply Schedule contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, awarded June 1, 2022, with a ceiling of $1,250,080 and completion through May 31, 2027. That vehicle enables VISN 12 to issue task orders for pharmaceutical and hematology-related products to Veterans Affairs medical centers. The Department of Health and Human Services Substance Abuse and Mental Health Services Administration (SAMHSA) represents the second-largest customer by award count, with seven sub-awards routed through the Tennessee Department of Mental Health and Substance Abuse Services as the prime grantee. The Department of Justice Office of Justice Programs Bureau of Justice Assistance accounts for three additional sub-awards.

Hikma's subcontractor work concentrates on naloxone supply and opioid-overdose-prevention medications delivered to Tennessee state substance-abuse agencies. Representative work includes a September 2025 sub-award to supply Kloxxado nasal spray in 8 mg doses at minimum cost for indigent populations, with twenty-four-hour order fulfillment and direct shipment to twenty-three state addresses; a January 2024 sub-award to provide naloxone through COVID-19 supplemental funding; and January 2024 sub-award work to ensure naloxone access for lay people and individuals at high overdose risk leaving treatment facilities. Activity peaked in 2024 with seven awards, followed by three awards in 2025 and one in 2026. The vendor's capability portfolio is narrowly framed around generic pharmaceutical supply chain execution, particularly injectable formulations, controlled substances for federal healthcare and substance-abuse treatment systems, and rapid fulfillment logistics. Combined obligated dollars across all awards stand at $3.8 million against a $10 million combined potential value ceiling (38% obligation rate), reflecting the early-stage nature of the FSS contract vehicle and ongoing sub-award ordering cycles.